Celastrol Alleviates Aortic Valve Calcification Via Inhibition of NADPH Oxidase 2 in Valvular Interstitial Cells
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
This study sought to investigate whether reactive oxygen species (ROS)-generating reduced nicotinamide adenine dinucleotide phosphate oxidase 2 (Nox2) contributes to calcific aortic valve disease (CAVD) or whether celastrol, a natural Nox2 inhibitor, may provide potential therapeutic target for CAVD. CAVD is an active and cellular-driven fibrocalcific process characterized by differentiation of aortic valvular interstitial cells (AVICs) toward an osteogenic-like phenotype. ROS levels increase in calcified aortic valves, while the sources of ROS and their roles in the pathogenesis of CAVD are elusive. The roles of Nox2 and the effects of celastrol were studied using cultured porcine AVICs in vitro and a rabbit CAVD model in vivo. Nox2 proteins were significantly upregulated in human aortic valves with CAVD. In vitro, Nox2 was markedly induced upon stimulation of AVICs with osteogenic medium, along with the increases in ROS production and calcium nodule formation. Celastrol significantly decreased calcium deposition of AVICs by 35%, with a reduction of ROS generation. Knockdown of endogenous Nox2 substantially suppressed AVIC calcification by 39%, the inhibitory effect being similar to celastrol treatment. Mechanistically, either celastrol treatment or knockdown of Nox2 significantly inhibited glycogen synthase kinase 3 beta/β-catenin signaling, leading to attenuation of fibrogenic and osteogenic responses of AVICs. In a rabbit CAVD model, administration of celastrol significantly reduced aortic valve ROS production, fibrosis, calcification, and severity of aortic stenosis, with less left ventricular dilatation and better preserved contractile function. Upregulation of Nox2 is critically involved in CAVD. Celastrol is effective to alleviate CAVD, likely through the inhibition of Nox2-mediated glycogen synthase kinase 3 beta/β-catenin pathway in AVICs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reactive Oxygen Species in Metabolic and Inflammatory Signaling
Forrester, S. J., Kikuchi, D. S., Hernandes, M. S., Xu, Q., & Griendling, K. K. (2018) · Circulation Research · doi:10.1161/circresaha.117.311401 · Cited by 2,081 · cited 2×
“It is well established that increased oxidative stress is a central pathophysiological component of numerous cardiovascular diseases including inflammation, metabolic disorder, and atherosclerosis (14), all of which are risk factors of CAVD (32).”
BackgroundIntensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644 · cited 1×
“The relationship between circulating cholesterol and CAVD has not been established in humans because large clinical trials failed to show any influence of lipidlowering therapy with statins on aortic stenosis (42,43).”
BackgroundMutations in NOTCH1 cause aortic valve disease
Garg, V., Muth, A. N., Ransom, J. F., Schluterman, M. K., Barnes, R., King, I. N., Grossfeld, P. D., & Srivastava, D. (2005) · Nature · doi:10.1038/nature03940 · Cited by 1,509
Lindman, B. R., Clavel, M.-A., Mathieu, P., Iung, B., Lancellotti, P., Otto, C. M., & Pibarot, P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.6 · Cited by 982 · cited 2×
“This phenotypic switch of quiescent AVICs to osteogenic myofibroblasts is supported by gene-profiling findings of increased valvular expression of osteoblast-specific marker proteins, such as osteopontin (OPN), and transcription factor, runtrelated transcription factor 2 (Runx2), which is essential for osteoblastic di…”
BackgroundChan, K. L., Teo, K., Dumesnil, J. G., Ni, A., & Tam, J. (2010) · Circulation · doi:10.1161/circulationaha.109.900027 · Cited by 815 · cited 1×
“The relationship between circulating cholesterol and CAVD has not been established in humans because large clinical trials failed to show any influence of lipidlowering therapy with statins on aortic stenosis (42,43).”
BackgroundTreatment of Obesity with Celastrol
Liu, J., Lee, J., Salazar Hernandez, M. A., Mazitschek, R., & Ozcan, U. (2015) · Cell · doi:10.1016/j.cell.2015.05.011 · Cited by 726 · cited 3×
“Celastrol was recently identified as a leptin sensitizer and potential novel antiobesity drug (19,20).”
BackgroundResidual NADPH Oxidase and Survival in Chronic Granulomatous Disease
Kuhns, D. B., Alvord, W. G., Heller, T., Feld, J. J., Pike, K. M., Marciano, B. E., Uzel, G., DeRavin, S. S., Priel, D. A. L., Soule, B. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007097 · Cited by 568 · cited 1×
“Another issue to consider with respect to targeted Nox2 inhibition is the potential to compromise neutrophil function, but previous work showed that this requires very substantial Nox2 inhibition (38), thus safe therapeutic targeting of cardiovascular Nox2 could be feasible.”
BackgroundSimard, L., Côté, N., Dagenais, F., Mathieu, P., Couture, C., Trahan, S., Bossé, Y., Mohammadi, S., Pagé, S., Joubert, P., et al. (2017) · Circulation Research · doi:10.1161/circresaha.116.309306 · Cited by 294 · cited 1×
“It was reported there were sex differences in the AV phenotypes, with female patients demonstrating a more fibrotic AVs and males a more calcific phenotype (51).”
BackgroundLiberman, M., Bassi, E., Martinatti, M. K., Lario, F. C., Wosniak, J., Pomerantzeff, P. M. A., & Laurindo, F. R. M. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.156745 · Cited by 225
Pioglitazone attenuates valvular calcification induced by hypercholesterolemia
Chu, Y., Lund, D. D., Weiss, R. M., Brooks, R. M., Doshi, H., Hajj, G. P., Sigmund, C. D., & Heistad, D. D. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.300794 · Cited by 49
Rezende, F., Prior, K.-K., Löwe, O., Wittig, I., Strecker, V., Moll, F., Helfinger, V., Schnütgen, F., Kurrle, N., Wempe, F., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.11.019 · Cited by 46 · cited 1×
“In addition, reduced nicotinamide adenine dinucleotide phosphate–dependent lucigenin chemiluminescence is an imperfect method to examine Nox activity (37).”
Method
Cited by
Calcific aortic valve disease: mechanisms, prevention and treatment
Moncla, L.-H. M., Briend, M., Bossé, Y., & Mathieu, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00845-7 · Cited by 306
Driscoll, K., Cruz, A. D., & Butcher, J. T. (2021) · Circulation Research · doi:10.1161/circresaha.121.318011 · Cited by 102
AVCAPIR: A Novel Procalcific PIWI-Interacting RNA in Calcific Aortic Valve Disease
Han, D., Zhou, T., Li, L., Ma, Y., Chen, S., Yang, C., Ma, N., Song, M., Zhang, S., Wu, J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065213 · Cited by 38
Metadata
- Authors
- Liu, H., Wang, L., Pan, Y., Wang, X., Ding, Y., Zhou, C., Shah, A. M., Zhao, G., & Zhang, M.
- Venue
- JACC: Basic to Translational Science
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 5
- Issue
- 1
- Pages
- 35-49
- ISSN
- 2452-302X (ISSN-L)
- OpenAlex
- W2996171710
- Cited by
- 67
- References
- 11
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.